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Introduction
Th e design of an immunosuppressive strategy must take 
into account the three major causes of morbidity follow-
ing organ transplantation: ischaemia–reperfusion injury 
(particularly in marginal donor organs); rejection; and 
complications of drug treatment (toxicity, infection and 
cancer). Induction immunosuppression is now used in 
the majority of transplant programmes in solid organ 
transplantation.
Induction therapy is intended to protect the graft from 
the immediate postoperative period of high rejection 
risk. However, there is increasing interest in the eﬀ ects of 
induction agents in mitigating the eﬀ ects of ischaemia–
reperfusion injury. With respect to mainte nance therapy, 
the priority in the early post operative weeks is to prevent 
rejection and minimise postsurgical infections and other 
surgical complications. Subse quently, drug toxicity, 
opportunistic infection and cancer risk become the 
primary concerns.
Despite several decades of experience, there is no 
consensus regarding many aspects of induction therapy. 
Both polyclonal antibodies and monoclonal antibodies 
are used with no clear evidence as to which is preferable. 
Similarly, there is little agreement as to whether depleting 
or nondepleting antibodies are preferable. Th ere is a 
range of targets from the highly selective anti-CD25 
antibodies (basiliximab) that target an antigen (the inter-
leukin-2 receptor) only present on activated lymphocytes 
to antibodies that recognise all peripheral blood lympho-
cytes (for example, antithymocyte globulin (ATG), 
alemtu zumab). Although anti-CD25 antibodies are very 
widely used globally, there is now increasing interest in 
the potential beneﬁ ts of depleting agents with a broader 
spectrum. Th e advantages that have been hypothesised 
for these agents include reduction of ischaemia–reper-
fusion injury, a more profound protection from early 
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acute rejection and, ﬁ nally, a long-lasting eﬀ ect in 
relation to donor-speciﬁ c hyporesponsiveness.
Alemtuzumab
Alemtuzumab (Campath) is a monoclonal antibody that 
recognises the CD52 antigen, present on all peripheral 
blood lymphocytes. Campath antibodies have been 
tested experimentally and clinically for 30 years [1].
Initially an IgM rat-derived antibody (Campath-1M) 
was used for the removal of T cells from bone marrow for 
transplantation; this was carried out as a means to 
prevent graft versus host disease. It was noted at the time 
that an antibody of profound lymphocyte-depleting capa-
bilities would have potential application in solid organ 
transplantation. Campath-1M was used in clinical renal 
transplant trials and was found to have a profound eﬀ ect 
on peripheral lymphocyte numbers, although with rapid 
recovery between doses [2], and was also shown to 
reduce the incidence of acute rejection [3]. Smaller 
studies with the IgG2b isotype (Campath-1G) demon-
strated a more profound and long-lasting depletion of 
lymphocytes [4].
Th e humanised antibody (Campath-1H) was developed 
with the potential advantages of greater eﬃ  cacy and, 
second, a lower risk of sensitisation. Th is antibody was 
used for (and subsequently licensed for) the treatment of 
chronic lymphocytic leukaemia [5]. Campath-1H was 
also used in a number of autoimmune conditions [6-8] 
and shown to be eﬀ ective in treating multiple sclerosis 
[9]. Th e ﬁ rst report of the use of the humanised antibody 
in solid organ transplantation was in the treatment of 
acute cellular rejection of kidney transplants [10], which 
was associated with a high incidence of infections.
Randomised trials of alemtuzumab in solid organ 
transplantation
A number of randomised trials of alemtuzumab in solid 
organ transplantation have been published. In 2008 
Margreiter and colleagues studied 131 patients random-
ised to receive induction therapy with alemtuzumab 
(2  ×  20  mg) versus no induction [11]. All patients were 
subsequently treated with tacrolimus and patients who 
had not received induction therapy also received myco-
phenolate. Th is trial demonstrated a signiﬁ cant reduction 
in the incidence of acute rejection at 6 months (29% vs. 
15%, P = 0.05). However, by 12 months the incidence of 
rejection was no longer signiﬁ cantly diﬀ er ent (32% vs. 
30%). Th ere was no diﬀ erence in renal function between 
the two groups and, apart from an increase in the 
incidence of cytomegalovirus infection, there was no 
other adverse consequence of induction therapy.
In 2011 Chan and colleagues reported a randomised 
controlled trial of 82 alemtuzumab-treated patients (with 
tacrolimus monotherapy) versus 42  controls (receiving 
dacluzimab, tacrolimus, mycophenolate), all patients 
having a rapid steroid taper [12]. Th is study showed a 
lower incidence of rejection in the alemtuzumab-treated 
group at 6 months but not 12 months and no diﬀ erence 
in graft survival or function. However, the study 
conﬁ rmed that alemtu zu mab therapy does enable simple 
and eﬀ ective tacrolimus monotherapy with a very low 
rate of rejection.
Also in 2011, Hanaway and colleagues carried out a 
randomised trial involving 474 kidney transplant 
recipients [13]. Th ese were divided into high-risk patients 
(deﬁ ned as panel reactive antibody >20%, black race, re-
transplant; n = 139) and low-risk patients (all others). Th e 
high-risk group was treated with either ATG (1.5  mg/
kg × 4, n = 70) or alemtuzumab (30 mg × 1, n = 69). Th e 
low-risk group of patients was treated with basiliximab 
(20  mg  ×  2, n  =  171) or alemtuzumab (30  mg  ×  1, 
n = 164). All patients received tacrolimus 8 to 14 ng/ml, 
mycophenolate 2 g/day, and steroids for 5 days. Patients 
were followed up for 3 years. Th is trial demonstrated that 
patients treated with alemtuzumab had a signiﬁ cantly 
lower incidence of cellular rejection at 6, 12 and 
36  months (3% vs. 15%, 5% vs. 17% and 13% vs. 20% 
respectively). When divided into the high-risk and low-
risk subgroups, it was clear that the reduction in rejection 
was entirely within the group of patients at low risk of 
rejection (alemtuzumab vs. basiliximab) and that the 
incidence of rejection in the high-risk patients was 
similar between the alemtuzumab and ATG groups. 
Th ere was no signiﬁ cant diﬀ erence in graft or patient 
survival. Analysis of lymphocyte populations demon-
strated that alemtuzumab and rabbit ATG had similar 
eﬀ ects with respect to lymphocyte depletion and the rate 
of recovery of lymphocyte populations. Th is was con-
trasted in the low-risk group, in which the lymphocyte 
population was profoundly suppressed by alemtuzumab 
but very little altered by treatment with basiliximab. 
Th ere was no eﬀ ect on renal function. Th is trial did show 
that alemtuzumab-treated patients are more liable to late 
rejection episodes (after 12 months), a ﬁ nding also noted 
by others including Watson and colleagues [14]. What is 
also notable from this and other large series of 
alemtuzumab-treated transplant patients is the relative 
absence of autoimmune complications, a problem that 
has been seen more commonly in patients treated for 
multiple sclerosis [15].
When the potency and duration of lymphocyte deple-
tion induced by alemtuzumab was recognised, a number 
of investigators considered whether this may lead to the 
induction of donor-speciﬁ c hyporesponsive ness. Th is 
followed the important observations of Knechtle and 
colleagues in demonstrating that profound lymphocyte 
depletion, using an anti-CD3 monoclonal antibody 
conjugated to diphtheria toxin, can lead to long-lasting 
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donor-speciﬁ c hyporesponsiveness in a non human 
primate experimental model of kidney trans plan tation 
[16]. Calne and colleagues tested the use of alemtuzumab 
induction (2 × 20 mg) followed by low-dose cyclosporin 
monotherapy (75 to 125  mg/ml) [17]. Th is study, 
although without a control group, demonstrated the 
capability of a low-dose mono therapy immunosup pres-
sion regimen to achieve low levels of rejection and good 
levels of graft survival and function. Th e same group of 
patients was reviewed 5  years after transplantation [14] 
and was compared with a group of matched controls 
treated with conventional therapy (cyclosporin, predniso-
lone, azathioprine). Lympho cyte counts were signiﬁ cantly 
lower in the alemtuzumab group only in the ﬁ rst 
3 months post operatively. Cyclosporin levels were signiﬁ -
cantly lower in the alemtuzumab group for approximately 
2 years. However, despite lower cyclosporin levels, there 
was no signiﬁ cant diﬀ erence in renal function. An early 
beneﬁ t with respect to acute rejection in the alem-
tuzumab-treated patients was matched by an increased 
level of rejection after 6 months, culminating in a similar 
overall level of rejection between the two groups. Th ere 
was no signiﬁ cant diﬀ erence in patient or graft survival 
or in the incidence of infection or other serious adverse 
events.
Alemtuzumab and mammalian target of rapamycin 
inhibitors
Th e ability to lower calcineurin inhibitor (CNI) doses was 
regarded as one of the primary advantages of alemtu zu-
mab therapy, particularly because of the desire to avoid 
chronic nephrotoxicity [18]. However, despite the ability 
of alemtuzumab to enable lower levels of CNI therapy, 
none of the above studies demonstrated improvement of 
renal function in patients treated with alemtuzumab. Th e 
profound lympho-depletion caused by alemtuzumab led 
Kirk and colleagues to question whether the antibody 
alone would enable tolerance and avoid the need for 
main tenance therapy. Seven living donor recipients were 
treated with three or four doses of alemtuzumab pre-
operatively; despite profound depletion of lymphocytes 
in the peripheral blood and lymph nodes, all patients 
developed rejection (reversible) and required conversion 
to maintenance sirolimus [19]. Th e availability of 
mammalian target of rapamycin inhibitors, however, 
provided the opportunity for long-term maintenance of 
patients without the use of nephrotoxic immuno-
suppression; the combination of alemtuzumab induction 
with sirolimus monotherapy was a theoretically attractive 
proposition.
In the ﬁ rst study of an immunosuppression strategy of 
this design, 29 patients were treated with alemtuzumab 
(20 mg × 2) followed by low-dose maintenance sirolimus 
therapy [20]. Eight patients required treatment for 
rejection and one graft was lost. Th e investigators con-
cluded that sirolimus monotherapy was inadequate in 
this context. Other investigators tested the combination 
of sirolimus with mycophenolate following alemtuzumab 
induction [21]. Twenty-two patients were treated with 
alemtuzumab induction (30  mg  ×  2) and maintenance 
therapy sirolimus (8 to 12  mg/ml) and mycophenolate 
(500  mg/twice daily). Th ere was an acute rejection 
incidence of 36%, leuko paenia in 27% of patients and 
acute respiratory distress syndrome in two patients. Th e 
investigators concluded that the combination of alem tu-
zumab, sirolimus and mycophenolate, when started at 
the time of trans plan tation, was associated with a high 
rejection rate and a high incidence of other complications.
Attention then moved to the use of alemtuzumab 
induction followed by a short course of CNI therapy, 
before switching to sirolimus maintenance therapy for 
the longer term. In a study of 30 patients, alemtuzumab 
(30  mg  ×  2) induction was followed by mycophenolate 
(500  mg/twice daily for 12  months), tacrolimus (5 to 
8 ng/ml for 6 months) and, after tacrolimus withdrawal, 
sirolimus (5 to 8 ng/ml) (data submitted for publication). 
A number of rejection episodes occurred following 
mycophenolate withdrawal at 12  months (all reversible 
with steroids) and the protocol was therefore amended to 
continue mycopheno late 250  mg twice daily thereafter. 
Th is protocol was associated with a low incidence of 
rejection (6.6% at 12  months). Following the change of 
protocol to maintain low-dose mycophenolate after 
12 months, there were no acute rejection episodes after 
12  months. Two patients were withdrawn from the 
protocol because of respiratory side eﬀ ects of sirolimus. 
Eighty-ﬁ ve per cent of patients remained steroid and CNI 
free 5 years postoperatively.
Th is trial demonstrated the potential utility of 
alemtuzumab in enabling patients to be established safely 
on CNI-free therapy. Th e real beneﬁ t of this strategy is in 
the potential absence of chronic nephrotoxicity and the 
consequent long-term improvement in graft half-life. 
Clearly this hypothesis required formal testing in an 
adequately powered randomised control clinical trial. 
Such a trial was established in 2010 with the intention of 
testing the eﬀ ects of alemtuzumab versus basiliximab as 
an induction agent and testing the eﬀ ect of switching to 
sirolimus from tacrolimus at 6  months. Th e end points 
for this study will ﬁ rst be the incidence of acute cellular 
rejection and then medium-term graft function. Th e 
results of this study (Campath, calcineurin inhibitor 
reduction, chronic allograft nephropathy) are awaited.
Abbreviations
ATG, antithymocyte globulin; CNI, calcineurin inhibitor.
Competing interests
PJF has received honoraria from Pfi zer for lecturing.
Friend Transplantation Research 2013, 2(Suppl 1):S5
http://www.transplantation research.com/supplements/2/S1/S5
Page 3 of 4
Declaration
This article has been published as part of Transplantation Research 
Volume 2 Suppl 1, 2013: Proceedings of the 12th International Symposium 
on Transplantation. The full contents of the supplement are available at 
http://www.transplantationresearch.com/supplements/2/S1. The supplement 
is based on the 12th International Transplantation Symposium held on 
16–17 April 2012, in Istanbul, Turkey. The symposium and publication based 
on these proceedings were supported by an unrestricted educational grant 
from Pfi zer Inc., who had no infl uence on the editorial content. Editorial 
support was provided by Synergy, Richmond, UK and was funded by Pfi zer 
Inc. Rapamune (sirolimus) is a product marketed by Pfi zer Inc. The articles have 
been through the journal’s standard peer review process and the Supplement 
Editors declare that they have no competing interests.
Published: 20 November 2013
References
1. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H: 
Removal of T cells from bone marrow for transplantation: a monoclonal 
antilymphocyte antibody that fi xes human complement. Blood 1983, 
62:873-882.
2. Hale G, Waldmann H, Friend P, Calne R: Pilot study of CAMPATH-1, a rat 
monoclonal antibody that fi xes human complement, as an 
immunosuppressant in organ transplantation. Transplantation 1986, 
42:308-311.
3. Friend PJ, Hale G, Waldmann H, Gore S, Thiru S, Joysey V, Evans DB, Calne RY: 
Campath-1M-prophylactic use after kidney transplantation. A randomised 
controlled clinical trial. Transplantation 1989, 48:248-253.
4. Friend PJ, Waldmann H, Hale G, Cobbold S, Rebello P, Thiru S, Jamieson NV, 
Johnston PS, Calne RY: Reversal of allograft rejection using the monoclonal 
antibody, Campath-1G. Transplant Proc 1991, 23:2253-2254.
5. Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, 
Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A: Phase II trial of 
subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-
1H) as fi rst-line treatment for patients with B-cell chronic lymphocytic 
leukemia (B-CLL). Blood 2002, 100:768-773.
6. Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, St Clair 
EW, Schnitzer TJ, Johnston JM: CAMPATH-1H in rheumatoid arthritis – an 
intravenous dose-ranging study. Br J Rheumatol 1996, 35:231-240.
7. Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, Isaacs JD: 
Campath-1H therapy in refractory ocular infl ammatory disease. Br J 
Ophthalmol 2000, 84:107-109.
8. Cheung WW, Hwang GY, Tse E, Kwong YL: Alemtuzumab induced complete 
remission of autoimmune hemolytic anemia refractory to corticosteroids, 
splenectomy and rituximab. Haematologica 2006, 91(5 Suppl):ECR13.
9. Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing 
M, Scolding N, Compston A: Preliminary evidence from magnetic 
resonance imaging for reduction in disease activity after lymphocyte 
depletion in multiple sclerosis. Lancet 1994, 344:298-301.
10. Friend PJ, Rebello P, Oliveira D, Manna V, Cobbold SP, Hale G, Jamieson NV, 
Jamieson I, Calne RY, Harris DT, et al.: Successful treatment of renal allograft 
rejection with a humanized antilymphocyte monoclonal antibody. 
Transplant Proc 1995, 27:869-870.
11. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne 
RY: Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal 
transplantation: results of a prospective randomized trial. Am J Transplant 
2008, 8:1480-1485.
12. Chan K, Taube D, Roufosse C, Cook T, Brookes P, Goodall D, Galliford J, Cairns T, 
Dorling A, Duncan N, Hakim N, Palmer A, Papalois V, Warrens AN, Willicombe 
M, McLean AG: Kidney transplantation with minimized maintenance: 
alemtuzumab induction with tacrolimus monotherapy – an open label, 
randomized trial. Transplantation 2011, 92:774-780.
13. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy 
R, Holman J; INTAC Study Group: Alemtuzumab induction in renal 
transplantation. N Engl J Med 2011, 364:1909-1919.
14. Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, Smith KG, Thiru 
S, Jamieson NV, Hale G, Waldmann H, Calne R: Alemtuzumab (CAMPATH 1H) 
induction therapy in cadaveric kidney transplantation – effi  cacy and 
safety at fi ve years. Am J Transplant 2005, 5:1347-1353.
15. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, 
Tandon PK: Alemtuzuma b vs. interferon beta-1a in early multiple sclerosis. 
N Engl J Med 2008, 359:1786-1801.
16. Knechtle SJ, Vargo D, Fechner J, Zhai Y, Wang J, Hanaway MJ, Scharff  J, Hu H, 
Knapp L, Watkins D, Neville DM Jr: FN18-CRM9 immunotoxin promotes 
tolerance in primate renal allografts. Transplantation 1997, 63:1-6.
17. Calne R, Friend P, Moff att S, Bradley A, Hale G, Firth J, Bradley J, Smith K, 
Waldmann H: Prope tolerance, perioperative Campath 1H, and low-dose 
cyclosporin monotherapy in renal allograft recipients. Lancet 1998, 
351:1701-1702.18. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, 
Chapman JR: The natural history of chronic allograft nephropathy. N Engl J 
Med 2003, 349:2326-2333.
19. Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoff mann SC, Kampen RL, Cendales 
LK, Tadaki DK, Harlan DM, Swanson SJ: Results from a human renal allograft 
tolerance trial evaluating the humanized CD52-specifi c monoclonal 
antibody alemtuzumab (CAMPATH-1H). Transplantation 2003, 76:120-129.
20. Knechtle SJ, Pirsch JD, H Fechner J Jr, Becker BN, Friedl A, Colvin RB, Lebeck 
LK, Chin LT, Becker YT, Odorico JS, D’Alessandro AM, Kalayoglu M, Hamawy 
MM, Hu H, Bloom DD, Sollinger HW: Campath-1H induction plus rapamycin 
monotherapy for renal transplantation: results of a pilot study. Am J 
Transplant 2003, 3:722-730.
21. Flechner SM, Friend PJ, Brockmann J, Ismail HR, Zilvetti M, Goldfarb D, Modlin 
C, Mastroianni B, Savas K, Devaney A, Simmonds M, Cook DJ: Alemtuzumab 
induction and sirolimus plus mycophenolate mofetil maintenance for CNI 
and steroid-free kidney transplant immunosuppression. Am J Transplant 
2005, 5:3009-3014.
doi:10.1186/2047-1440-2-S1-S5
Cite this article as: Friend PJ: Alemtuzumab induction therapy in solid 
organ transplantation. Transplantation Research 2013, 2(Suppl 1):S5.
Friend Transplantation Research 2013, 2(Suppl 1):S5
http://www.transplantation research.com/supplements/2/S1/S5
Page 4 of 4
